We are initiating coverage on Diurnal Group, which is developing and commercialising multiple products from the class of steroid hormones. The company’s first product, Alkindi, is marketed in the United States and Europe and it is aiming to launch its second product, Chronocort, in 2021. These products are oral formulations of hydrocortisone developed to treat disorders of the adrenal glands. Additionally, Diurnal is developing an oral testosterone, DITEST, which will be re-entering the clinic i ....
12 Mar 2021
Diurnal Group - Improving treatments for endocrine disorders
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Diurnal Group - Improving treatments for endocrine disorders
- Published:
12 Mar 2021 -
Author:
Dr Nathaniel Calloway -
Pages:
15
We are initiating coverage on Diurnal Group, which is developing and commercialising multiple products from the class of steroid hormones. The company’s first product, Alkindi, is marketed in the United States and Europe and it is aiming to launch its second product, Chronocort, in 2021. These products are oral formulations of hydrocortisone developed to treat disorders of the adrenal glands. Additionally, Diurnal is developing an oral testosterone, DITEST, which will be re-entering the clinic i ....